TuHURA Biosciences, Inc. borrowed an additional $650,000 under its existing revolving credit facility with Parkview Holdings One LLC on September 14, 2026. The funds are intended for general corporate purposes. This draw is part of a broader Loan Agreement established in April 2026 that provides up to $50 million in availability and matures in April 2031. TuHURA Biosciences operates as a clinical-stage biotechnology company focused on developing therapies for rare diseases.
